Post by Future Biotech Expo

The biotech IPO market has a new king. Parabilis Medicines raised $670 million in its initial public offering on June 9, 2026, selling 33.5 million shares at $20 per share, making it the largest venture-backed biotech IPO in history. The number is staggering on its own, but the context makes it more impressive. The offering was upsized twice in a single day, blowing past the company's original $476 million target and a revised $553 million plan before landing at $670 million. Regeneron Pharmaceuticals added another $75 million through a concurrent private placement tied to a new research partnership, bringing total proceeds closer to $745 million. The stock now trades on Nasdaq under the ticker PBLS, and closed its first day at $31.60, a 58% jump above the IPO price, signaling the market's conviction in what Parabilis is building. Read more: https://lnkd.in/gmd_Y9cX #FutureBiotechExpo #FBE26 #Biotech #LifeSciences #HealthcareInnovation #DrugDiscovery #ClinicalResearch #Biotechnology #HoustonEvents